203 related articles for article (PubMed ID: 23327575)
1. CYP3A4 intron 6 C>T SNP (CYP3A4*22) encodes lower CYP3A4 activity in cancer patients, as measured with probes midazolam and erythromycin.
Elens L; Nieuweboer A; Clarke SJ; Charles KA; de Graan AJ; Haufroid V; Mathijssen RH; van Schaik RH
Pharmacogenomics; 2013 Jan; 14(2):137-49. PubMed ID: 23327575
[TBL] [Abstract][Full Text] [Related]
2. Impact of POR*28 on the clinical pharmacokinetics of CYP3A phenotyping probes midazolam and erythromycin.
Elens L; Nieuweboer AJ; Clarke SJ; Charles KA; de Graan AJ; Haufroid V; van Gelder T; Mathijssen RH; van Schaik RH
Pharmacogenet Genomics; 2013 Mar; 23(3):148-55. PubMed ID: 23324807
[TBL] [Abstract][Full Text] [Related]
3. Comparative performance of oral midazolam clearance and plasma 4β-hydroxycholesterol to explain interindividual variability in tacrolimus clearance.
Vanhove T; de Jonge H; de Loor H; Annaert P; Diczfalusy U; Kuypers DR
Br J Clin Pharmacol; 2016 Dec; 82(6):1539-1549. PubMed ID: 27501475
[TBL] [Abstract][Full Text] [Related]
4. Effect of erlotinib on CYP3A activity, evaluated in vitro and by dual probes in patients with cancer.
Calvert H; Twelves C; Ranson M; Plummer R; Fettner S; Pantze M; Ling J; Hamilton M; Lum BL; Rakhit A
Anticancer Drugs; 2014 Aug; 25(7):832-40. PubMed ID: 24637575
[TBL] [Abstract][Full Text] [Related]
5. Association of genotypes of the CYP3A cluster with midazolam disposition in vivo.
Miao J; Jin Y; Marunde RL; Gorski CJ; Kim S; Quinney S; Radovich M; Li L; Hall SD
Pharmacogenomics J; 2009 Oct; 9(5):319-26. PubMed ID: 19506580
[TBL] [Abstract][Full Text] [Related]
6. Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients.
Lepper ER; Baker SD; Permenter M; Ries N; van Schaik RH; Schenk PW; Price DK; Ahn D; Smith NF; Cusatis G; Ingersoll RG; Bates SE; Mathijssen RH; Verweij J; Figg WD; Sparreboom A
Clin Cancer Res; 2005 Oct; 11(20):7398-404. PubMed ID: 16243813
[TBL] [Abstract][Full Text] [Related]
7. Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women.
Floyd MD; Gervasini G; Masica AL; Mayo G; George AL; Bhat K; Kim RB; Wilkinson GR
Pharmacogenetics; 2003 Oct; 13(10):595-606. PubMed ID: 14515058
[TBL] [Abstract][Full Text] [Related]
8. Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes.
Mathijssen RH; de Jong FA; van Schaik RH; Lepper ER; Friberg LE; Rietveld T; de Bruijn P; Graveland WJ; Figg WD; Verweij J; Sparreboom A
J Natl Cancer Inst; 2004 Nov; 96(21):1585-92. PubMed ID: 15523087
[TBL] [Abstract][Full Text] [Related]
9. The CYP3A4*22 C>T single nucleotide polymorphism is associated with reduced midazolam and tacrolimus clearance in stable renal allograft recipients.
de Jonge H; Elens L; de Loor H; van Schaik RH; Kuypers DR
Pharmacogenomics J; 2015 Apr; 15(2):144-52. PubMed ID: 25287072
[TBL] [Abstract][Full Text] [Related]
10. CYP3A5*3 and bilirubin predict midazolam population pharmacokinetics in Asian cancer patients.
Seng KY; Hee KH; Soon GH; Sapari NS; Soong R; Goh BC; Lee LS
J Clin Pharmacol; 2014 Feb; 54(2):215-24. PubMed ID: 24214410
[TBL] [Abstract][Full Text] [Related]
11. Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam.
Kharasch ED; Walker A; Isoherranen N; Hoffer C; Sheffels P; Thummel K; Whittington D; Ensign D
Clin Pharmacol Ther; 2007 Oct; 82(4):410-26. PubMed ID: 17554244
[TBL] [Abstract][Full Text] [Related]
12. Relationships between Endogenous Plasma Biomarkers of Constitutive Cytochrome P450 3A Activity and Single-Time-Point Oral Midazolam Microdose Phenotype in Healthy Subjects.
Woolsey SJ; Beaton MD; Choi YH; Dresser GK; Gryn SE; Kim RB; Tirona RG
Basic Clin Pharmacol Toxicol; 2016 Apr; 118(4):284-91. PubMed ID: 26399557
[TBL] [Abstract][Full Text] [Related]
13. Evidence of CYP3A allosterism in vivo: analysis of interaction between fluconazole and midazolam.
Yang J; Atkins WM; Isoherranen N; Paine MF; Thummel KE
Clin Pharmacol Ther; 2012 Mar; 91(3):442-9. PubMed ID: 22048224
[TBL] [Abstract][Full Text] [Related]
14. CYP3A pharmacogenetics and tacrolimus disposition in adult heart transplant recipients.
Deininger KM; Vu A; Page RL; Ambardekar AV; Lindenfeld J; Aquilante CL
Clin Transplant; 2016 Sep; 30(9):1074-81. PubMed ID: 27314545
[TBL] [Abstract][Full Text] [Related]
15. The P450 oxidoreductase genotype is associated with CYP3A activity in vivo as measured by the midazolam phenotyping test.
Oneda B; Crettol S; Jaquenoud Sirot E; Bochud M; Ansermot N; Eap CB
Pharmacogenet Genomics; 2009 Nov; 19(11):877-83. PubMed ID: 19801957
[TBL] [Abstract][Full Text] [Related]
16. Probe of CYP3A by a single-point blood measurement after oral administration of midazolam in healthy elderly volunteers.
Krupka E; Venisse N; Lafay C; Gendre D; Diquet B; Bouquet S; Perault MC
Eur J Clin Pharmacol; 2006 Aug; 62(8):653-9. PubMed ID: 16832678
[TBL] [Abstract][Full Text] [Related]
17. Factors influencing midazolam hydroxylation activity in human liver microsomes.
He P; Court MH; Greenblatt DJ; von Moltke LL
Drug Metab Dispos; 2006 Jul; 34(7):1198-207. PubMed ID: 16638818
[TBL] [Abstract][Full Text] [Related]
18. Influence of solute carriers on the pharmacokinetics of CYP3A4 probes.
Franke RM; Baker SD; Mathijssen RH; Schuetz EG; Sparreboom A
Clin Pharmacol Ther; 2008 Dec; 84(6):704-9. PubMed ID: 18509328
[TBL] [Abstract][Full Text] [Related]
19. Effect of mibefradil on CYP3A4 in vivo.
Veronese ML; Gillen LP; Dorval EP; Hauck WW; Waldman SA; Greenberg HE
J Clin Pharmacol; 2003 Oct; 43(10):1091-100. PubMed ID: 14517191
[TBL] [Abstract][Full Text] [Related]
20. Progressive decline in tacrolimus clearance after renal transplantation is partially explained by decreasing CYP3A4 activity and increasing haematocrit.
de Jonge H; Vanhove T; de Loor H; Verbeke K; Kuypers DR
Br J Clin Pharmacol; 2015 Sep; 80(3):548-59. PubMed ID: 26114223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
